Literature DB >> 8350986

Characterization of human brain kynurenine aminotransferases using [3H]kynurenine as a substrate.

W Schmidt1, P Guidetti, E Okuno, R Schwarcz.   

Abstract

The brain metabolite kynurenic acid is an established broad-spectrum antagonist at ionotropic excitatory amino acid receptors. In the human brain, two distinct enzymes are capable of synthesizing kynurenic acid from its bioprecursor L-kynurenine. Using [3H]kynurenine as the substrate, the two kynurenine aminotransferases (kynurenine aminotransferase I and kynurenine aminotransferase II) are now characterized using partially purified enzyme preparations. When assayed at its pH optimum of 10.0, kynurenine aminotransferase I showed pronounced oxo acid specificity (pyruvate >> 2-oxoglutarate). This co-substrate selectivity was lost when assays were performed at pH 7.4. Kynurenine aminotransferase I activity was potently inhibited by 2 mM glutamine, tryptophan or phenylalanine, but not by 2 mM alpha-aminoadipate or glutamate. In contrast to kynurenine aminotransferase I, kynurenine aminotransferase II showed a shallow pH curve with an optimum of about 7.4, displayed virtually equal activity with all of the nine 2-oxo acids tested and was not susceptible to inhibition by any of 10 amino acids (2 mM) which are known to serve as substrates for enzymatic transamination. Kinetic analyses, performed at pH 7.4 (kynurenine aminotransferases I and II) and 10.0 (kynurenine aminotransferase I), and using various concentrations of kynurenine, pyruvate or 2-oxoglutarate, respectively, substantiated the differences between the two enzymes and further elucidated the pH dependence of kynurenine aminotransferase I activity [apparent Km values for kynurenine with 1 mM 2-oxoglutarate: 515 microM (pH 7.4) and 22 microM (pH 10.0)]. Taken together, these data suggest that under physiological conditions, human brain kynurenic acid may derive preferentially from kynurenine aminotransferase II.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350986     DOI: 10.1016/0306-4522(93)90464-q

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

2.  Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93).

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Etsuo Okuno; Martyna Kandefer-Szerszen; Jan Albrecht; Waldemar A Turski
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

Review 3.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

4.  Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.

Authors:  Jamison B Tuttle; Marie Anderson; Bruce M Bechle; Brian M Campbell; Cheng Chang; Amy B Dounay; Edelweiss Evrard; Kari R Fonseca; Xinmin Gan; Somraj Ghosh; Weldon Horner; Larry C James; Ji-Young Kim; Laura A McAllister; Jayvardhan Pandit; Vinod D Parikh; Brian J Rago; Michelle A Salafia; Christine A Strick; Laura E Zawadzke; Patrick R Verhoest
Journal:  ACS Med Chem Lett       Date:  2012-10-24       Impact factor: 4.345

5.  Cysteine and keto acids modulate mosquito kynurenine aminotransferase catalyzed kynurenic acid production.

Authors:  Qian Han; Jianyong Li
Journal:  FEBS Lett       Date:  2004-11-19       Impact factor: 4.124

Review 6.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Thermal stability, pH dependence and inhibition of four murine kynurenine aminotransferases.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  BMC Biochem       Date:  2010-05-19       Impact factor: 4.059

8.  Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor.

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Jolanta Parada-Turska; Barbara Zdzisinska; Robert Rejdak; Tomasz Kocki; Etsuo Okuno; Martyna Kandefer-Szerszen; Eberhart Zrenner; Waldemar A Turski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-10       Impact factor: 3.000

9.  Biochemical and structural properties of mouse kynurenine aminotransferase III.

Authors:  Qian Han; Howard Robinson; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Mol Cell Biol       Date:  2008-11-24       Impact factor: 4.272

Review 10.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.